Epilepsy meets cancer: when, why, and what to do about it?

Details

Serval ID
serval:BIB_7EEF12E369E3
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Epilepsy meets cancer: when, why, and what to do about it?
Journal
Lancet Oncology
Author(s)
Weller M., Stupp R., Wick W.
ISSN
1474-5488 (Electronic)
ISSN-L
1470-2045
Publication state
Published
Issued date
2012
Volume
13
Number
9
Pages
e375-e382
Language
english
Notes
Publication types: Journal Article- Review sur le site éditeur et dans Wos
Abstract
The lifetime risk of having epileptic seizures is profoundly increased in patients with cancer: about 20% of all patients with systemic cancer may develop brain metastases. These patients and those with primary brain tumours have a lifetime risk of epilepsy of 20-80%. Moreover, exposure to chemotherapy or radiotherapy to the brain, cancer-related metabolic disturbances, stroke, and infection can provoke seizures. The management of epilepsy in patients with cancer includes diagnosis and treatment of the underlying cerebral pathological changes, secondary prophylaxis with antiepileptic drugs, and limiting of the effect of epilepsy and its treatment on the efficacy and tolerability of anticancer treatments, cognitive function, and quality of life. Because of the concern of drug-drug interactions, the pharmacological approach to epilepsy requires a multidisciplinary approach, specifically in a setting of rapidly increasing choices of agents both to treat cancer and cancer-associated epilepsy.
Pubmed
Web of science
Create date
04/10/2012 17:07
Last modification date
20/08/2019 14:39
Usage data